BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/14/2026 8:39:32 AM | Browse: 1 | Download: 15
 |
Received |
|
2025-07-15 23:19 |
|
Peer-Review Started |
|
2025-07-15 23:20 |
|
First Decision by Editorial Office Director |
|
2025-08-05 08:57 |
|
Return for Revision |
|
2025-08-05 08:57 |
|
Revised |
|
2025-10-09 17:26 |
|
Publication Fee Transferred |
|
2025-10-13 16:49 |
|
Second Decision by Editor |
|
2025-12-09 02:44 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-12-09 07:51 |
|
Articles in Press |
|
2025-12-09 07:51 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-01-07 00:25 |
|
Publish the Manuscript Online |
|
2026-01-14 08:39 |
| ISSN |
2220-3230 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Transplantation |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Outcomes of basiliximab vs alemtuzumab induction in kidney allograft recipients with matched immunological Profiles: A retrospective cohort study
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Chukwuma A Chukwu, Philip A Kalra, Marcus Lowe, Kay Poulton, Titus Augustine and Anirudh Rao |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Chukwuma A Chukwu, Consultant, PhD, Department of Nephrology, Liverpool University Hospitals NHS Foundation Trust, Mount Vernon Street, Liverpool L7 8YE, Mersey Side, United Kingdom. chukwuma.chukwu@rlbuht.nhs.uk |
| Key Words |
Kidney transplantation; Immunosuppression induction; Alemtuzumab; Basiliximab; Graft outcomes |
| Core Tip |
This retrospective cohort study compared real-world outcomes of alemtuzumab and basiliximab induction in kidney transplant recipients from two tertiary centers in North-West England, one routinely using alemtuzumab and the other exclusively basiliximab. Using propensity score matching to reduce confounding, we evaluated graft function, graft and patient survival, acute rejection, infection, and other long-term complications. Alemtuzumab induction was found to be associated with lower estimated glomerular filtration rate, and higher risks of cytomegalovirus and BK viremia, post-transplant malignancy, and death-censored graft loss compared with basiliximab. These findings emphasize the need for individualized selection of induction therapy, balancing the potent immunosuppressive effects of alemtuzumab against its potential for adverse outcomes, and support tailored approaches based on recipient risk profile and center-specific experience. |
| Publish Date |
2026-01-14 08:39 |
| Citation |
Chukwu CA, Kalra PA, Lowe M, Poulton K, Augustine T, Rao A. Outcomes of basiliximab vs alemtuzumab induction in kidney allograft recipients with matched immunological Profiles: A retrospective cohort study. World J Transplant 2026; 16(1): 111959 |
| URL |
https://www.wjgnet.com/2220-3230/full/v16/i1/111959.htm |
| DOI |
https://dx.doi.org/10.5500/wjt.v16.i1.111959 |
© 2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
